13D·WATCH Activist + Insider Intelligence Live feed Blog About Pilot
SCHEDULE 13D Filed 2026-04-24 Event 2025-04-17 SEC 0001999371-26-009036 →

TPG GP A, LLC ACHIEVE LIFE SCIENCES, INC. ACHV

Stake: 12.60% Shares: 13,755,160 CUSIP: 004468500 Class: Common Stock, par value $0.001 per share

Item 4 — Purpose of Transaction

The information set forth in or incorporated by reference in Items 2, 3, 5 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. Securities Purchase Agreement TPG Auriga entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with the Issuer, dated as of April 15, 2026, pursuant to which it agreed to purchase, and the Issuer agreed to sell and issue, 6,877,580 shares of Common Stock and 6,877,580 accompanying Warrants at a collective price of $3.635 per combination of share of Common Stock and accompany Warrant (the "Private Placement"). On April 17, 2026, the Private Placement closed (the "Closing"). The aggregate purchase price of $25,000,003.30 paid by TPG Auriga for the shares of Common Stock and accompanying Warrants was funded by equity contributions of the limited partners of TPG Auriga. Pursuant to the Securities Purchase Agreement, on April 15, 2026, the Board of Directors of the Issuer appointed Lucian Iancovici, as designated by TPG Auriga, to serve as a director of the Issuer, effective April 17, 2026. The Issuer has agreed to nominate Dr. Iancovici for re-election to the Board of Directors at the Issuer's 2026 annual meeting of stockholders and the 2027 annual meeting of stockholders, until such time as TPG Auriga beneficially owns less than 5% of the Issuer's outstanding Common Stock. Registration Rights Agreement In connection with the Private Placement, TPG Auriga entered into a Registration Rights Agreement (the "Registration Rights Agreement") with the Issuer, dated as of April 15, 2026, providing for the registration under the Securities Act of 1933, as amended, for resale of the shares of Common Stock issued at Closing and the shares of Common Stock issuable upon exercise of the Warrants. Other than as described above, none of the Reporting Persons nor, to the best knowledge of each of the Reporting Persons, without independent verification, any of the TPG GP A Officers, currently has any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although the Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto. As a result of these activities, one or more of the Reporting Persons may suggest or take a position with respect to potential changes in the operations, management or capital structure of the Issuer as a means of enhancing shareholder value. Such suggestions or positions may include one or more plans or proposals that relate to or would result in any of the actions required to be reported herein, including, without limitation, such matters as acquiring additional securities of the Issuer or disposing of securities of the Issuer(greek question mark) entering into an extraordinary corporate transaction such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries(greek question mark) selling or transferring a material amount of assets of the Issuer or any of its subsidiaries(greek question mark) changing the present board of directors or management of the Issuer, including changing the number or term of directors or filling any existing vacancies on the board of directors of the Issuer(greek question mark) materially changing the present capitalization or dividend policy of the Issuer(greek question mark) materially changing the Issuer's business or corporate structure(greek question mark) changing the Issuer's certificate of incorporation, bylaws or instruments corresponding thereto or taking other actions which may impede the acquisition of control of the Issuer by any person(greek question mark) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association(greek question mark) causing a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Act of 1933, as amended(greek question mark) and taking any action similar to any of those enumerated above. Reference to and description of the Warrants, Securities Purchase Agreement and Registration Rights Agreement set forth above in this Item 4 do not purport to be complete and are qualified in their entirety by reference to the full text of the form of Common Warrant, form of Securities Purchase Agreement and form of Registration Rights Agreement, which have been filed as Exhibits 2, 3 and 4 and are incorporated herein by this reference.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
2 13D/G filings on this issuer
1 other filing besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest · settle 2026-03-31
DTC 6.79
7,117,982 shares short · +1.5% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $374K
Point72 Asset Mgmt

Other 13D/G Filings on ACHIEVE LIFE SCIENCES, INC.

FiledFormFilerStakeShares
2026-04-27 SCHEDULE 13D venBio Global Strategic Fund V, L.P. 9.99% 10,737,317 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →